10x Genomics Inc-A 2025年季度报告

Washington, D.C. 20549 FORM10-Q_____________________ (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch31, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number:001-39035 10x Genomics, Inc. (Exact name of registrant as specified in its charter) 45-5614458(I.R.S. EmployerIdentificationNo.) 6230 Stoneridge Mall RoadPleasanton,California(Address of principle executive offices) (925)401-7300(Registrant’s telephone number, including area code) N/A(Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule12b-2of theExchange Act. Large accelerated filer☒Non-accelerated filer☐ Acceleratedfiler☐Smallerreportingcompany☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2of theExchange Act).Yes☐No☒ As of April30, 2025, the registrant had111,092,774shares of Class A common stock, $0.00001 par value per share, outstanding and12,040,976shares of Class B common stock, $0.00001 par value per share, outstanding. Table of Contents PARTI.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations4Condensed Consolidated Statements of Comprehensive Loss5Condensed Consolidated Statements of Stockholders’Equity6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures about Market Risk23Item 4.Controls and Procedures23PARTII.OTHER INFORMATION24Item1.Legal Proceedings24Item1A.Risk Factors24Item 5.Other Information70Item 6.Exhibits71Signatures72 10x Genomics, Inc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to those sections’ “safeharbor.” All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as “may,”“might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,”“estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or variations of these terms or similar terminology generallycan identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statementsinclude statements regarding 10x Genomics, Inc.’s expectations regarding our plans, objectives, goals, beliefs, business strategies,results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions,factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected futureinvestments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them,expected uses, performance and benefits of our products and services, business trends and other information. These statements arebased on management’s expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing andshould not be relied upon as 10x Genomics, Inc.’s views as of any su